Synapto-depressive effects of amyloid beta require PICK1

Area of Science:

• Neuroscience
• Molecular Biology
• Pharmacology

Background:

• Alzheimer's disease (AD) involves amyloid beta (Aβ) impacting excitatory synapses.
• The precise mechanisms of Aβ-induced synaptic weakening remain unclear.
• Protein interacting with C kinase 1 (PICK1) is a potential mediator.

Purpose of the Study:

• To elucidate the role of PICK1 in Aβ-mediated synaptic dysfunction.
• To investigate the interaction between Aβ, PICK1, and AMPA receptors.
• To identify therapeutic targets for Aβ-induced synaptic damage.

Main Methods:

• Utilized knockout mice lacking PICK1 to assess Aβ effects on synaptic transmission.
• Examined surface expression of GluA2 subunits in cultured neurons exposed to Aβ.
• Employed structure-based drug design to develop a small molecule inhibitor (BIO922) targeting the GluA2-PICK1 interaction.

Main Results:

• Mice lacking PICK1 showed no Aβ-induced depression of synaptic transmission.
• Aβ failed to reduce surface GluA2 levels in PICK1-deficient neurons.
• The novel small molecule BIO922 successfully blocked Aβ's effects on synapses and surface receptors.

Conclusions:

• PICK1 is essential for Aβ to weaken excitatory synapses.
• The interaction between GluA2 and PICK1 is a critical pathway for Aβ's synaptic toxicity.
• Targeting the GluA2-PICK1 interaction represents a promising therapeutic strategy for Alzheimer's disease.